Abstract：【Objective】To investigate the curative effect of inhaled acetylcysteine combined with ulinastatin in the treatment of severe pneumonia.【Methods】A total of 110 patients with severe pneumonia admitted to our hospital from March 2021 to March 2023 were randomly divided into control group(receiving inhaled acetylcysteine combined with anti-infection treatment) and the observation group(receiving combined ulinastatin treatment on the basis of control group) with a ratio of 1∶1(55 cases in each group).All patients were treated for 2 weeks. The clinical efficacy, the time of fever reduction, the time of lung rales and cough disappearance, and the incidence of adverse reactions were compared between the two groups. Serum inflammatory factors [interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), C-reactive protein(CRP)], blood gas analysis indicators [PaO2, SaO2 and PaCO2], acute physiology and chronic health status score System Ⅱ(APACHEⅡ) score were compared as well.【Results】The total effective rate of the observation group was 90.91%, which was significantly higher than 76.36% of the control group, and the difference was statistically significant(P<0.05). The time of fever reduction and disappearance of lung rales and cough in the observation group were significantly shorter than those in the control group(P<0.05). After 2 weeks of treatment, the levels of IL-6, TNF-α, CRP and PaCO2 in observation group were lower than those in control group(P<0.05), while PaO2 and SaO2 were significantly higher than those in control group(P<0.05). After 2 weeks of treatment, the physiological scores and chronic health status scores of the observation group were significantly lower than those of the control group, with statistical significance(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】Inhaled acetylcysteine combined with ulinastatin is effective in the treatment of patients with severe pneumonia, which can effectively improve respiratory function and reduce inflammation without increasing the incidence of adverse reactions.It is worthy of clinical application.
侯福建, 魏召辉, 赵月伟. 吸入性乙酰半胱氨酸联合乌司他丁治疗重症肺炎的临床疗效[J]. 医学临床研究, 2024, 41(5): 722-724.
HOU Fujian, WEI Zhaohui, ZHAO Yuewei. Observation of the Therapeutic Effects of Inhaled N-acetylcysteine Combined with Ustekinumab in the Treatment of Severe Pneumonia. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 722-724.
2024, Vol. 41 
